• KOL
    • Severity Scores
    • Jiuyang Xu
    • Jiuyang Xu: Influence Statistics

      Jiuyang Xu

      Jiuyang Xu

      Tsinghua University School of Medicine, Beijing, China. | Tsinghua University School of Medicine, Beijing, People’s Republic of China | Tsinghua University School of Medicine, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jiuyang Xu:Expert Impact

      Concepts for whichJiuyang Xuhas direct influence:Severity scores,Hospital survivors,Human metapneumovirus,Adult inpatients,Viral sepsis,Corticosteroids treatment,Coronavirus oc43,Human coronavirus oc43.

      Jiuyang Xu:KOL impact

      Concepts related to the work of other authors for whichfor which Jiuyang Xu has influence:Clinical characteristics,Coronavirus disease covid19,Sarscov2 infection,Disease 2019,Hospitalized patients,Cytokine storm,Acute respiratory.

      KOL Resume for Jiuyang Xu

      Year
      2021

      Tsinghua University School of Medicine, Beijing, China.

      Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China

      2020

      China-Japan Friendship Hospital - Institute of Clinical Medical Sciences

      Tsinghua University School of Medicine, Beijing, 100084 China

      2018

      Department of Pediatrics, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 15224, USA; Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jiuyang Xu is among the top experts in the world.
      Concept World rank
      mendelian randomization covid19 #1
      ritonavir sars #1
      publication beijing covid19 #2
      months disease emergence #2
      basic characteristics 2019ncov #2
      550 deaths #2
      previous epidemics decades #2
      pandemics sars cov2 #2
      drugs 2019 #2
      disease emergence experience #2
      exam 2019 coronavirus #2
      incoming challenges china #2
      order incoming challenges #2
      2019ncov unanswered questions #2
      drugs 2019ncov #2
      quiz exam #2
      interferonβ convalescent plasma #2
      2019ncov emerging pathogen #2
      randomization covid19 #2
      efficient preliminary work #2
      letter china #3
      disease mechanism covid19 #3
      disease pathogenesis progress #3
      portrait clinical features #3
      multiple antiviral therapies #3
      practice significance #3
      coronavirus infections hospitals #3
      immune suppression phase #3
      shock autopsy #3
      genetic resistance barrier #3
      hostacting antivirals #3
      covid19 basic science #3
      2019 coronavirus outbreak #3
      viral sepsis covid19 #3
      officials citizens #3
      china continuous #4
      macrophages pandemics #4
      weak peripheral pulses #4
      acei arb regimen #4
      drug creation #4
      102 eligible studies #4
      overt hypotension #4
      aor acei arb #4
      viral rnaaemia association #4
      Sign-in to see all concepts, it's free!

      Prominent publications by Jiuyang Xu

      KOL-Index: 17765

      BACKGROUND: Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described.

      METHODS: In this retrospective, multicentre cohort study, we included all adult ...

      Known for Adult Inpatients | Survivors Risk Factors | Jinyintan Hospital | China Wuhan | Fibrin Fibrinogen
      KOL-Index: 15558

      BACKGROUND: A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.

      METHODS: All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by ...

      Known for 41 Patients | Viral Prognosis Radiography | 2019 Coronavirus Wuhan | Ncov Infection | Common Symptoms
      KOL-Index: 14862

      BACKGROUND: The full range of long-term health consequences of COVID-19 in patients who are discharged from hospital is largely unclear. The aim of our study was to comprehensively compare consequences between 6 months and 12 months after symptom onset among hospital survivors with COVID-19.

      METHODS: We undertook an ambidirectional cohort study of COVID-19 survivors who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7 and May 29, 2020. At 6-month and 12-month ...

      Known for 12 Months | Hospital Survivors | Anxiety Depression | Longitudinal Cohort | 6 Month
      KOL-Index: 14764

      BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

      METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less ...

      Known for Standard Time | Ritonavir Sars | Severe Illness | Treatment Lopinavir | Clinical Improvement
      KOL-Index: 7734

      Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63, and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 ...

      Known for Human Coronavirus | Spike Protein | Neutralizing Antibodies | Reactive Antibody | Sarscov2 Seasonal Hcovs
      KOL-Index: 7525

      Since the outbreak of coronavirus disease 2019 (COVID-19), clinicians have tried every effort to understand the disease, and a brief portrait of its clinical features have been identified. In clinical practice, we noticed that many severe or critically ill COVID-19 patients developed typical clinical manifestations of shock, including cold extremities and weak peripheral pulses, even in the absence of overt hypotension. Understanding the mechanism of viral sepsis in COVID-19 is warranted ...

      Known for Viral Sepsis | Coronavirus Disease Covid19 | Cov2 Sars | Disease Mechanism | Basic Science
      KOL-Index: 7327

      Rapidly progressing hypoxemia and acute respiratory distress syndrome were commonly observed in patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) viral pneumonia [1]. Although several severity scores including Pneumonia Severity Index (PSI) [2], CURB-65 and CRB-65 (confusion, (urea >7 mmol·L−1), respiratory rate ≥30 breaths·min−1, blood pressure <90 mmHg (systolic) ≤60 mmHg (diastolic), age ≥65 years), [3], A-DROP [4] and SMART-COP [5] have been developed to ...

      Known for Severity Scores | Covid19 Pneumonia | Viral Predictive | Patients Risk | 2 News2
      KOL-Index: 6687

      OBJECTIVES: Use of corticosteroids is common in the treatment of coronavirus disease 2019, but clinical effectiveness is controversial. We aimed to investigate the association of corticosteroids therapy with clinical outcomes of hospitalized COVID-19 patients.

      METHODS: In this single-centre, retrospective cohort study, adult patients with confirmed coronavirus disease 2019 and dead or discharged between 29 December 2019 and 15 February 2020 were studied; 1:1 propensity score matchings ...

      Known for Corticosteroids Treatment | Mechanical Ventilation | Hospital Mortality | Death Patients | Corticosteroid Therapy
      KOL-Index: 6575

      The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate. We performed a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, who had definite clinical outcome (dead or discharged) by February 15, 2020. Patients on anti-hypertensive treatment with or without ACEI/ARB were compared on their clinical characteristics and ...

      Known for Acei Arb | Enzyme Inhibitors | Antihypertensive Agents | Angiotensin Receptor | Patients Hypertension
      KOL-Index: 5621

      The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, ...

      Known for 2019 Coronavirus | Antiviral Drugs | Respiratory Syndrome | Lopinavir Ritonavir | Monoclonal Antibodies
      KOL-Index: 5409

      BACKGROUND: The characteristics of neutralizing antibodies (NAbs) and antibody against major antigen proteins related to clinical outcomes in severe coronavirus disease 2019 (COVID-19) patients were still less known.

      METHODS: NAbs and antibodies targeting nucleocapsid (N), spike protein (S), and the receptor-binding domain (RBD) in longitudinal plasma samples from the LOTUS China trial were measured by microneutralization assay and enzyme-linked immunosorbent assay (ELISA). Viral load ...

      Known for Antibody Responses | Lotus China Trial | Igg Antibodies | Spike Protein | Covid19 China
      KOL-Index: 4129

      There have been arguments on whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment alters the risk of coronavirus disease 2019 (COVID-19) susceptibility and disease severity. We identified a total of 102 eligible studies for systematic review, in which 49 studies adjusting for confounders were included in the meta-analysis. We found no association between prior ACEI/ARB use and risk of severe acute respiratory syndrome coronavirus 2 ...

      Known for Acei Arb | Covid19 Angiotensin | Converting Enzyme | Receptor Antagonists | Humans Hypertension
      KOL-Index: 3235

      The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, ...

      Known for 2019 Coronavirus | Antiviral Drugs | Wuhan China | Respiratory Illness | Lopinavir Ritonavir
      KOL-Index: 2259
      Known for Covid19 Outbreak | Coronavirus Infections | Pneumonia Viral | Laboratory Techniques | China Clinical
      KOL-Index: 2105

      Human metapneumovirus (HMPV) is a non-segmented, negative strand RNA virus belonging to the family Pneumoviridae, previously a subfamily of Paramyxoviridae. It is a leading cause of lower respiratory tract infection in infants, children, and adults with underlying medical conditions. HMPV grows poorly in cell culture and requires trypsin to cleave and mature the virus particles, which adds to the challenge of HMPV research. Currently, an indirect immuno-staining assay is commonly used to ...

      Known for Human Metapneumovirus | Plaque Assay | Cell Culture | Load Viral | Paramyxoviridae Infections

      Key People For Severity Scores

      Top KOLs in the world
      #1
      JeanLouis MD JeanLouis
      septic shock severe sepsis critically patients
      #2
      Derek C Angus
      severe sepsis united states septic shock
      #3
      Jack E MD Zimmerman
      acute physiology hospital mortality mechanical ventilation
      #4
      Douglas P PhD Wagner
      hospital mortality apache iii risk adjustment
      #5
      Rui Paulo Moreno
      septic shock mechanical ventilation organ failure
      #6
      William A Knaus
      acute physiology intensive monitoring sepsis syndrome

      Tsinghua University School of Medicine, Beijing, China. | Tsinghua University School of Medicine, Beijing, People’s Republic of China | Tsinghua University School of Medicine, Beijing, China | Dept of Pulmonary and Critical Care Medicine, Center of R

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.